{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:16:45Z","timestamp":1790983005411,"version":"4.1.0"},"reference-count":18,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Background: Next-generation sequencing (NGS)-detected ERBB2 amplification occurs in a subset of urothelial carcinomas, but its role as a treatment-selection marker for trastuzumab deruxtecan (T-DXd) remains uncertain. Methods: We retrospectively reviewed four patients with metastatic urothelial carcinoma treated with T-DXd in routine practice from 2024. Treatment selection was based on NGS-detected ERBB2 amplification because HER2 immunohistochemistry and in situ hybridization were unavailable. Results: Four men aged 65\u201376 years received T-DXd: one in the second line and three in the fourth or fifth line. The best radiological responses, abstracted from contemporaneous radiology reports and oncology medical records, were complete response in one patient, partial response in one, and stable disease in two. Three patients had previously received enfortumab vedotin. Documented adverse events included fatigue, anemia, diarrhea, rash, and leukopenia. No interstitial lung disease or pneumonitis was documented in the available records. Conclusions: These observations are descriptive and hypothesis-generating. They do not establish the efficacy or safety of T-DXd or validate ERBB2 amplification as a predictive biomarker, but they support prospective evaluation of genomic ERBB2 amplification when standard HER2 testing is unavailable.<\/jats:p>","DOI":"10.3390\/curroncol33080456","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:09:42Z","timestamp":1785398982000},"page":"456","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series"],"prefix":"10.3390","volume":"33","author":[{"given":"Giuseppe","family":"Di Lorenzo","sequence":"first","affiliation":[{"name":"Oncology Unit, \u201cAndrea Tortora\u201d Hospital, ASL Salerno, 84016 Pagani, Italy"},{"name":"School of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy"},{"name":"Associazione ORA ETS, 84134 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5205-7788","authenticated-orcid":false,"given":"Sara","family":"Di Lorenzo","sequence":"additional","affiliation":[{"name":"Oncology Unit, ASL NA3 Sud, 80059 Torre del Greco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Verde","sequence":"additional","affiliation":[{"name":"Oncology Unit, \u201cAndrea Tortora\u201d Hospital, ASL Salerno, 84016 Pagani, Italy"},{"name":"Associazione ORA ETS, 84134 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Strianese","sequence":"additional","affiliation":[{"name":"Oncology Unit, \u201cAndrea Tortora\u201d Hospital, ASL Salerno, 84016 Pagani, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Leo","sequence":"additional","affiliation":[{"name":"Oncology Unit, ASL NA3 Sud, 80059 Torre del Greco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Buonerba","sequence":"additional","affiliation":[{"name":"Oncology Unit, \u201cAndrea Tortora\u201d Hospital, ASL Salerno, 84016 Pagani, Italy"},{"name":"Associazione ORA ETS, 84134 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2400879","DOI":"10.1200\/PO-24-00879","article-title":"Testing and interpretation of human epidermal growth factor receptor 2 protein expression and ERBB2 gene amplification in advanced urothelial carcinoma","volume":"9","author":"Koshkin","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102351","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1200\/JCO.2026.44.7_suppl.734","article-title":"Trastuzumab deruxtecan in pretreated patients with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in Part 1 of DESTINY-PanTumor02","volume":"44","author":"Jung","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.23.02626","article-title":"Trastuzumab deruxtecan in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA testing: A multicenter, single-arm, phase II basket trial","volume":"42","author":"Yagisawa","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): An international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with HER2-positive locally advanced or metastatic urothelial carcinoma: A combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma: A phase Ib\/II study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2025.04.009","article-title":"Bulumtatug fuvedotin in advanced solid tumors: A first-in-human phase I\/II study","volume":"36","author":"Zhang","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.annonc.2025.11.013","article-title":"Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors","volume":"37","author":"Zhu","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s12672-025-02457-8","article-title":"Progress of antibody-drug conjugates in the treatment of locally advanced or metastatic urothelial carcinoma: Opportunities and challenges","volume":"16","author":"Zeng","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The Double Antibody Drug Conjugate phase I trial of sacituzumab govitecan plus enfortumab vedotin in metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/456\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:56:02Z","timestamp":1785401762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["curroncol33080456"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33080456","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}